Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3236248 | 0.93 | CYP1A1 (0.49) | CYP1A1CYP1B1ESR1CYP1A2PTGS2 | |
| SCHEMBL3236239 | 0.93 | CYP1A1 (0.49) | CYP1A1CYP1B1ESR1CYP1A2PTGS2 | |
| SCHEMBL3238576 | 0.86 | NFE2L2 (0.56) | CYP1A1CYP1B1ESR1CYP1A2PTGS2 | |
| SCHEMBL3234318 | 0.86 | CYP19A1 (0.50) | APPCYP1A1CYP1B1ESR1CYP1A2 | |
| SCHEMBL1194745 | 0.86 | NFE2L2 (0.56) | CYP1A1CYP1B1ESR1CYP1A2PTGS2 | |
| SCHEMBL3234563 | 0.86 | NFE2L2 (0.58) | CYP1A1CYP1B1ESR1CYP1A2PTGS2 | |
| SCHEMBL3234312 | 0.86 | CYP19A1 (0.50) | APPCYP1A1CYP1B1ESR1CYP1A2 | |
| SCHEMBL1195443 | 0.86 | NFE2L2 (0.58) | CYP1A1CYP1B1ESR1CYP1A2PTGS2 | |
| SCHEMBL1195422 | 0.86 | MAOA (0.52) | CYP1A1CYP1B1ESR1CYP1A2PTGS2 | |
| SCHEMBL3153066 | 0.84 | CYP1A1 (0.54) | CYP1A1CYP1B1ESR1CYP1A2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056953-B2 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1173160-B1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040229959-A1 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-11-18 | — | — | US | disclosed |
| US-6787667-B2 | POLYSULFONSTYRENE POLYMER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-09-07 | — | — | US | disclosed |
| US-6762207-B1 | TARGETING RECEPTOR TYROSINE KINASES; SELECTIVE TUMOR CELL APOPTOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-13 | — | — | US | disclosed |
| US-20030216535-A1 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-11-20 | — | — | US | disclosed |
| EP-1173160-A4 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1173160-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000059495-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216535-A1 | (E)-styryl sulfone anticancer agents | KRAS, CCNE1, MCL1 | APP 4681/4885CYP1A1 1515/4885CYP1B1 1263/4885 |
| US-20040229959-A1 | (E)-styryl sulfone anticancer agents | SULT1E1, CCNE1, RPS3A | APP 4705/4885CYP1A1 2238/4885CYP1B1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.